This Article Full Text Full Text (PDF) CME: Take the course for this article: Preoperative Therapy in Breast Cancer: Lessons from the Treatment of Local... eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wolff, A. C. Articles by Davidson, N. E. Search for Related Content PubMed PubMed Citation Articles by Wolff, A. C. Articles by Davidson, N. E.

Preoperative Therapy in Breast Cancer: Lessons from the Treatment of Locally Advanced Disease

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Correspondence: Antonio C. Wolff, M.D., The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein Cancer Research Building, Room 189, 1650 Orleans Street, Baltimore, Maryland 21231-1000, USA. Telephone: 410-614-4192; Fax: 410-955-0125; e-mail: awolff{at}jhmi.edu

The greater use of screening has changed the stage distribution of breast cancer, and an increasing number of patients are diagnosed with earlier stages of the disease. Still, locally advanced breast cancer (LABC) remains a major clinical problem in the United States and a common presentation in many parts of the world. There is no standard definition of LABC. One commonly used includes patients with large primary tumors greater than 5 cm (T3) or with skin/chest wall involvement (T4), and/or fixed axillary (N2) or ipsilateral internal mammary (N3) lymph node involvement. According to the tumor node metastasis staging, these usually include stage IIIa (T0-2N2 or T3N1-2) and stage IIIb (T4Nx or TxN3) disease. Inflammatory breast cancer (T4d) is included in most classifications despite its distinct clinical behavior and worse prognosis overall, but it serves as an example of combined modality intervention. Historically, the term LABC has been applied to those clinical presentations where the disease is considered inoperable. However, these therapeutic principles (including preoperative or primary systemic therapy [PST]) are increasingly being applied to patients presenting with tumors greater than 5 cm and negative lymph nodes (stage IIb—T3N0) or even smaller tumors, who are considered to have operable disease and a better outcome than those traditionally classified as having LABC. PST is increasingly being used in otherwise operable stage I and II patients aiming at greater rates of breast conservation and earlier efficacy assessment. This article reviews many of these issues and ongoing research questions.

Key Words. Preoperative therapy • Neoadjuvant therapy • Locally advanced disease

This article has been cited by other articles:

				O Camara, M Rengsberger, A Egbe, A Koch, M Gajda, U Hammer, C Jorke, C Rabenstein, M Untch, and K Pachmann The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer Ann. Onc., September 1, 2007; 18(9): 1484 - 1492. [Abstract] [Full Text] [PDF]

				S. A. Narod and K. Offit Prevention and Management of Hereditary Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1656 - 1663. [Full Text] [PDF]

				O. Modlich, H.-B. Prisack, M. Munnes, W. Audretsch, and H. Bojar Immediate Gene Expression Changes After the First Course of Neoadjuvant Chemotherapy in Patients with Primary Breast Cancer Disease Clin. Cancer Res., October 1, 2004; 10(19): 6418 - 6431. [Abstract] [Full Text] [PDF]